Hospitalization and Emergency Department Encounters for COVID-19 After Paxlovid Treatment — California, December 2021–May 2022
Deborah E. Malden, Vennis Hong, Bruno Lewin, Bradley K. Ackerson, Marc Lipsitch, Joseph A. Lewnard, Sara Y. Tartof
Abstract
Underlying medical conditions were defined according to the modified Charlson Comorbidity Index, which included 17 conditions of interest available in EHRs during the 12 months preceding the date of treatment. Conditions included immunosuppressive disorders, acute myocardial infarction, congestive heart failure, peripheral vascular disease, cerebrovascular disease, dementia, chronic obstructive pulmonary disease, rheumatoid disease, peptic ulcer disease, mild and moderate liver disease, severe liver disease, diabetes with severe complications, diabetes without severe complications, hemiplegia or paraplegia, renal disease, cancer, and HIV/AIDS. Patients were considered to have received treatment with Paxlovid if they had documentation of a pharmacy dispensation of Paxlovid in their EHRs. ** Patients were considered to have a confirmed COVID-19-related hospital admission or ED encounter if their EHRs indicated that COVID-19 was either the primary reason for the encounter or if there was documentation of symptoms consistent with COVID-19 according to the latest CDC definition.